{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:23:54Z","timestamp":1790634234095,"version":"4.1.0"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.bpg.2021.101756","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T18:37:18Z","timestamp":1623868638000},"page":"101756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology"],"prefix":"10.1016","volume":"54-55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4087-9032","authenticated-orcid":false,"given":"Suwasin","family":"Udomkarnjananun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marith I.","family":"Francke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda C.M.","family":"De Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0925-3771","authenticated-orcid":false,"given":"Midas B.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla C.","family":"Baan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herold J.","family":"Metselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3840-0213","authenticated-orcid":false,"given":"Caroline M.","family":"den Hoed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Hesselink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7\u20138","key":"10.1016\/j.bpg.2021.101756_bib1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.clinbiochem.2017.01.007","article-title":"Therapeutic drug monitoring - key to personalized pharmacotherapy","volume":"50","author":"Oellerich","year":"2017","journal-title":"Clin Biochem"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/FTD.0000000000000627","article-title":"Improving therapeutic decisions: pharmacodynamic monitoring as an integral part of therapeutic drug monitoring","volume":"41","author":"Shipkova","year":"2019","journal-title":"Ther Drug Monit"},{"issue":"Suppl 3","key":"10.1016\/j.bpg.2021.101756_bib3","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"issue":"8222","key":"10.1016\/j.bpg.2021.101756_bib4","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0140-6736(81)91971-1","article-title":"Immunological and pharmacological monitoring in the clinical use of cyclosporin A","volume":"317","author":"Keown","year":"1981","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bpg.2021.101756_bib5","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/tri.12554","article-title":"Mycophenolate revisited","volume":"28","author":"van Gelder","year":"2015","journal-title":"Transpl Int"},{"issue":"1","key":"10.1016\/j.bpg.2021.101756_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000169","article-title":"TAC-TIC use of tacrolimus-based regimens in lupus nephritis","volume":"3","author":"Kraaij","year":"2016","journal-title":"Lupus Sci Med"},{"issue":"12","key":"10.1016\/j.bpg.2021.101756_bib7","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.ejca.2014.04.013","article-title":"Therapeutic drug monitoring in cancer--are we missing a trick?","volume":"50","author":"Bardin","year":"2014","journal-title":"Eur J Canc"},{"key":"10.1016\/j.bpg.2021.101756_bib8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.trac.2015.11.016","article-title":"Recent advances in therapeutic drug monitoring of immunosuppressive drugs","volume":"79","author":"Freudenberger","year":"2016","journal-title":"Trac Trends Anal Chem"},{"issue":"11","key":"10.1016\/j.bpg.2021.101756_bib9","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.tibtech.2020.03.001","article-title":"On-site therapeutic drug monitoring","volume":"38","author":"Ates","year":"2020","journal-title":"Trends Biotechnol"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib10","doi-asserted-by":"crossref","first-page":"E35","DOI":"10.1111\/j.1399-0012.2009.01166.x","article-title":"A clinical assessment of mycophenolate drug monitoring after liver transplantation","volume":"24","author":"Hwang","year":"2010","journal-title":"Clin Transplant"},{"issue":"5","key":"10.1016\/j.bpg.2021.101756_bib11","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1034\/j.1600-6143.2003.00079.x","article-title":"Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies","volume":"3","author":"Shaw","year":"2003","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.trre.2015.01.002","article-title":"Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management","volume":"29","author":"Shuker","year":"2015","journal-title":"Transplant Rev"},{"issue":"Suppl s1","key":"10.1016\/j.bpg.2021.101756_bib13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/ajt.15674","article-title":"OPTN\/SRTR 2018 annual data report: liver","volume":"20","author":"Kwong","year":"2020","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.bpg.2021.101756_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40262-018-0676-z","article-title":"Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of ulcerative colitis","volume":"58","author":"Berends","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bpg.2021.101756_bib15","article-title":"Tacrolimus as an effective and durable second-line treatment for chronic autoimmune hepatitis: a multicentric study","volume":"Aug 29","author":"Ferre-Aracil","year":"2020","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.bpg.2021.101756_bib16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/11317350-000000000-00000","article-title":"Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I","volume":"49","author":"Staatz","year":"2010","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.bpg.2021.101756_bib17","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/00007691-200410000-00008","article-title":"Changes in tacrolimus distribution in blood and plasma protein binding following liver transplantation","volume":"26","author":"Zahir","year":"2004","journal-title":"Ther Drug Monit"},{"issue":"10","key":"10.1016\/j.bpg.2021.101756_bib18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/FPC.0b013e328364db84","article-title":"PharmGKB summary: cyclosporine and tacrolimus pathways","volume":"23","author":"Barbarino","year":"2013","journal-title":"Pharmacogenetics Genom"},{"issue":"4","key":"10.1016\/j.bpg.2021.101756_bib19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1399-0012.2009.01143.x","article-title":"Evaluation of tacrolimus abbreviated area-under-the-curve monitoring in renal transplant patients who are potentially at risk for adverse events","volume":"24","author":"Hon","year":"2010","journal-title":"Clin Transplant"},{"issue":"3","key":"10.1016\/j.bpg.2021.101756_bib20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1442-2042.1995.tb00444.x","article-title":"Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients--importance of trough level as a practical indicator","volume":"2","author":"Ihara","year":"1995","journal-title":"Int J Urol"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00007691-199804000-00014","article-title":"An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants","volume":"20","author":"Ku","year":"1998","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/j.bpg.2021.101756_bib22","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0272-6386(00)70013-8","article-title":"Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients","volume":"35","author":"Wong","year":"2000","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.bpg.2021.101756_bib23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/01.ftd.0000158080.61201.65","article-title":"Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients","volume":"27","author":"Armend\u00e1riz","year":"2005","journal-title":"Ther Drug Monit"},{"issue":"8","key":"10.1016\/j.bpg.2021.101756_bib24","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1177\/0091270003254797","article-title":"Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection","volume":"43","author":"Tada","year":"2003","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.bpg.2021.101756_bib25","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00228-007-0354-9","article-title":"Evaluation of limited sampling strategies for tacrolimus","volume":"63","author":"Op den Buijsch","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.bpg.2021.101756_bib26","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1111\/j.1523-1755.2005.00352.x","article-title":"AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients","volume":"67","author":"Scholten","year":"2005","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1373\/clinchem.2013.213264","article-title":"Calcineurin activity assay measurement by liquid chromatography-tandem mass spectrometry in the multiple reaction monitoring mode","volume":"60","author":"Carr","year":"2014","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib28","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.clpt.2005.04.008","article-title":"Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients","volume":"78","author":"Fukudo","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.bpg.2021.101756_bib29","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1111\/bcp.13367","article-title":"NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation","volume":"83","author":"Bremer","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.bpg.2021.101756_bib30","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/tid.12206","article-title":"Reduced residual gene expression of nuclear factor of activated T cells-regulated genes correlates with the risk of cytomegalovirus infection after liver transplantation","volume":"16","author":"Steinebrunner","year":"2014","journal-title":"Transpl Infect Dis"},{"issue":"7","key":"10.1016\/j.bpg.2021.101756_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201113","article-title":"Analysis of NFATc1 amplification in T cells for pharmacodynamic monitoring of tacrolimus in kidney transplant recipients","volume":"13","author":"Kannegieter","year":"2018","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.bpg.2021.101756_bib32","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/ajt.12191","article-title":"Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(\u2020)","volume":"13","author":"Bouamar","year":"2013","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.bpg.2021.101756_bib33","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/00007890-199402270-00008","article-title":"FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects","volume":"57","author":"B\u00e4ckman","year":"1994","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.bpg.2021.101756_bib34","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1111\/j.1600-6143.2012.04140.x","article-title":"Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis","volume":"12","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2012","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/lt.21657","article-title":"Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients","volume":"15","author":"Nashan","year":"2009","journal-title":"Liver Transplant"},{"issue":"4S","key":"10.1016\/j.bpg.2021.101756_bib36","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/TP.0000000000001651","article-title":"Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the consensus on managing modifiable risk in transplantation (COMMIT) group","volume":"101","author":"Neuberger","year":"2017","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.bpg.2021.101756_bib37","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/lt.20520","article-title":"The renal-sparing efficacy of basiliximab in adult living donor liver transplantation","volume":"11","author":"Lin","year":"2005","journal-title":"Liver Transplant"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib38","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1600-6143.2008.02493.x","article-title":"Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study","volume":"9","author":"Neuberger","year":"2009","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.bpg.2021.101756_bib39","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/TP.0000000000002147","article-title":"International liver transplantation society consensus statement on immunosuppression in liver transplant recipients","volume":"102","author":"Charlton","year":"2018","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.bpg.2021.101756_bib40","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s12072-020-10091-5","article-title":"Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group","volume":"14","author":"Cillo","year":"2020","journal-title":"Hepatology International"},{"issue":"3","key":"10.1016\/j.bpg.2021.101756_bib41","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jhep.2020.09.016","article-title":"Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis","volume":"74","author":"Wahlin","year":"2021","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.bpg.2021.101756_bib42","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.jhep.2020.07.023","article-title":"Second-line and third-line therapy for autoimmune hepatitis: a position statement from the European reference Network on hepatological diseases and the international autoimmune hepatitis group","volume":"73","author":"Lohse","year":"2020","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2021.101756_bib43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.bpg.2021.101756_bib44","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1111\/bcp.13958","article-title":"Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose","volume":"85","author":"Berger","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.bpg.2021.101756_bib45","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/FPC.0b013e3283642fb3","article-title":"Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation","volume":"23","author":"Rojas","year":"2013","journal-title":"Pharmacogenetics Genom"},{"issue":"4","key":"10.1016\/j.bpg.2021.101756_bib46","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/FTD.0000000000000032","article-title":"Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis","volume":"36","author":"Buendia","year":"2014","journal-title":"Ther Drug Monit"},{"issue":"11","key":"10.1016\/j.bpg.2021.101756_bib47","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1373\/clinchem.2011.165613","article-title":"A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients","volume":"57","author":"Elens","year":"2011","journal-title":"Clin Chem"},{"issue":"3","key":"10.1016\/j.bpg.2021.101756_bib48","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit"},{"issue":"6","key":"10.1016\/j.bpg.2021.101756_bib49","first-page":"721","article-title":"Optimization of initial tacrolimus dose using pharmacogenetic testing","volume":"87","author":"Thervet","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.bpg.2021.101756_bib50","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1097\/TP.0000000000000708","article-title":"Improved tacrolimus target concentration achievement using computerized dosing in renal transplant recipients--A prospective, randomized study","volume":"99","author":"St\u00f8rset","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.bpg.2021.101756_bib51","article-title":"Avoiding tacrolimus under- and overexposure with a dosing algorithm for renal transplant recipients: a single arm prospective intervention trial","volume":"Jan 15","author":"Francke","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.bpg.2021.101756_bib52","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/ajt.13691","article-title":"A randomized controlled trial comparing the efficacy of Cyp3a5 genotype-based with body-weight-based tacrolimus dosing after living donor kidney transplantation","volume":"16","author":"Shuker","year":"2016","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.bpg.2021.101756_bib53","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/imj.13412","article-title":"Individualised medicine: why we need Bayesian dosing","volume":"47","author":"Donagher","year":"2017","journal-title":"Intern Med J"},{"key":"10.1016\/j.bpg.2021.101756_bib54","article-title":"Tacrolimus exposure prediction using machine learning","volume":"Nov 30","author":"Woillard","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bpg.2021.101756_bib55","doi-asserted-by":"crossref","first-page":"105578","DOI":"10.1016\/j.phrs.2021.105578","article-title":"Estimation of drug exposure by machine learning based on simulations from published pharmacokinetic models: the example of tacrolimus","volume":"167","author":"Woillard","year":"2021","journal-title":"Pharmacol Res"},{"issue":"4","key":"10.1016\/j.bpg.2021.101756_bib56","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40262-017-0567-8","article-title":"A population pharmacokinetic model to predict the individual starting dose of tacrolimus following pediatric renal transplantation","volume":"57","author":"Andrews","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.bpg.2021.101756_bib57","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1111\/ajt.13309","article-title":"Pharmacokinetics and toxicity of tacrolimus early after heart and lung transplantation","volume":"15","author":"Sikma","year":"2015","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.bpg.2021.101756_bib58","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00002018-200225100-00003","article-title":"Drug interactions with tacrolimus","volume":"25","author":"van Gelder","year":"2002","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.bpg.2021.101756_bib59","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/ajt.15199","article-title":"Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: establishing baseline values","volume":"19","author":"Leino","year":"2019","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.bpg.2021.101756_bib60","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1080\/1744666X.2020.1693263","article-title":"Impact of low tacrolimus exposure and high tacrolimus intra-patient variability on the development of de novo anti-HLA donor-specific antibodies in kidney transplant recipients","volume":"15","author":"Mendoza Rojas","year":"2019","journal-title":"Expet Rev Clin Immunol"},{"issue":"8","key":"10.1016\/j.bpg.2021.101756_bib61","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1111\/ajt.16002","article-title":"A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation","volume":"20","author":"Gonzales","year":"2020","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.bpg.2021.101756_bib62","first-page":"36","article-title":"The effects of intrapatient variability in tacrolimus concentration on clinical outcomes immediately after liver transplantation","volume":"30","author":"Kim","year":"2020","journal-title":"Kor J Clin Psychol"},{"issue":"16","key":"10.1016\/j.bpg.2021.101756_bib63","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.3748\/wjg.v24.i16.1795","article-title":"High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation","volume":"24","author":"Del Bello","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.bpg.2021.101756_bib64","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1097\/TP.0000000000002052","article-title":"High intrapatient variability of tacrolimus exposure in the early period after liver transplantation is associated with poorer outcomes","volume":"102","author":"Rayar","year":"2018","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.bpg.2021.101756_bib65","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1097\/TP.0000000000002680","article-title":"High intrapatient variability in tacrolimus exposure is not associated with immune-mediated graft injury after liver transplantation","volume":"103","author":"van der Veer","year":"2019","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib66","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/cpt.1618","article-title":"Intrapatient variability of tacrolimus exposure in solid organ transplantation: a novel marker for clinical outcome","volume":"107","author":"Kuypers","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.bpg.2021.101756_bib67","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/TP.0b013e3182292426","article-title":"Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients","volume":"92","author":"Wu","year":"2011","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib68","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/FTD.0000000000000136","article-title":"Conversion from twice-daily to once-daily tacrolimus does not reduce intrapatient variability in tacrolimus exposure","volume":"37","author":"Shuker","year":"2015","journal-title":"Ther Drug Monit"},{"issue":"6","key":"10.1016\/j.bpg.2021.101756_bib69","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/FTD.0000000000000205","article-title":"Impact of laboratory practices on interlaboratory variability in therapeutic drug monitoring of immunosuppressive drugs","volume":"37","author":"Christians","year":"2015","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.bpg.2021.101756_bib70","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/dta.2290","article-title":"Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs","volume":"10","author":"Zhang","year":"2018","journal-title":"Drug Test Anal"},{"issue":"1","key":"10.1016\/j.bpg.2021.101756_bib71","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1432-2277.2011.01365.x","article-title":"Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study","volume":"25","author":"Capron","year":"2012","journal-title":"Transpl Int"},{"issue":"5","key":"10.1016\/j.bpg.2021.101756_bib72","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/FTD.0000000000000780","article-title":"Measuring intracellular concentrations of calcineurin inhibitors: expert consensus from the international association of therapeutic drug monitoring and clinical toxicology expert panel","volume":"42","author":"Lemaitre","year":"2020","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.bpg.2021.101756_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230195","article-title":"Pharmacogenetic-Whole blood and intracellular pharmacokinetic-Pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients","volume":"15","author":"Tron","year":"2020","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.bpg.2021.101756_bib74","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.clinbiochem.2014.12.018","article-title":"Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells","volume":"48","author":"Lemaitre","year":"2015","journal-title":"Clin Biochem"},{"issue":"5","key":"10.1016\/j.bpg.2021.101756_bib75","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/FTD.0000000000000539","article-title":"Longitudinal study of tacrolimus in lymphocytes during the first year after kidney transplantation","volume":"40","author":"Klaasen","year":"2018","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/j.bpg.2021.101756_bib76","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/bcp.14585","article-title":"Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients","volume":"87","author":"Francke","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bpg.2021.101756_bib77","article-title":"Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5\/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients","volume":"Mar 1","author":"Sallustio","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.bpg.2021.101756_bib78","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/FTD.0b013e3181aa36cd","article-title":"New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation","volume":"31","author":"de Jonge","year":"2009","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.bpg.2021.101756_bib79","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.transproceed.2011.01.096","article-title":"A comparison of mycophenolate mofetil with mycophenolate sodium in renal transplant recipients on tacrolimus-based treatment","volume":"43","author":"Aptaramanov","year":"2011","journal-title":"Transplant Proc"},{"issue":"4","key":"10.1016\/j.bpg.2021.101756_bib80","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/TP.0b013e3181ca860d","article-title":"Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients","volume":"89","author":"Sollinger","year":"2010","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib81","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.trre.2011.01.002","article-title":"Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of the Transplantation Society consensus meeting","volume":"25","author":"Le Meur","year":"2011","journal-title":"Transplant Rev"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib82","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.trre.2010.06.001","article-title":"Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure","volume":"25","author":"Tett","year":"2011","journal-title":"Transplant Rev"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib83","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","article-title":"Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology","volume":"43","author":"Bergan","year":"2021","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1016\/j.bpg.2021.101756_bib84","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1046\/j.1600-6143.2005.00779.x","article-title":"Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2","volume":"5","author":"Hesselink","year":"2005","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.bpg.2021.101756_bib85","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/0149-2918(95)80084-0","article-title":"Drug interactions in transplantation","volume":"17","author":"Seifeldin","year":"1995","journal-title":"Clin Therapeut"},{"issue":"9","key":"10.1016\/j.bpg.2021.101756_bib86","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1093\/ndt\/gfm219","article-title":"Mycophenolic acid (MPA) and its glucuronide metabolites interact with transport systems responsible for excretion of organic anions in the basolateral membrane of the human kidney","volume":"22","author":"Wolff","year":"2007","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.bpg.2021.101756_bib87","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","article-title":"Clinical pharmacokinetics of mycophenolate mofetil","volume":"34","author":"Bullingham","year":"1998","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib88","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2215\/CJN.07111009","article-title":"Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation","volume":"5","author":"Kuypers","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib89","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.trre.2010.12.001","article-title":"Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation: a consensus report","volume":"25","author":"Cantarovich","year":"2011","journal-title":"Transplant Rev"},{"issue":"5","key":"10.1016\/j.bpg.2021.101756_bib90","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1517\/17425255.2016.1170806","article-title":"Therapeutic drug monitoring of mycophenolate in adult solid organ transplant patients: an update","volume":"12","author":"Kiang","year":"2016","journal-title":"Expet Opin Drug Metabol Toxicol"},{"issue":"10","key":"10.1016\/j.bpg.2021.101756_bib91","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1097\/TP.0000000000002762","article-title":"Optimizing mycophenolic acid exposure in kidney transplant recipients: time for target concentration intervention","volume":"103","author":"Metz","year":"2019","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.bpg.2021.101756_bib92","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/FTD.0b013e318068619d","article-title":"Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoring","volume":"29","author":"Budde","year":"2007","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib93","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/FTD.0b013e3182a37a1e","article-title":"Limited sampling model for advanced mycophenolic acid therapeutic drug monitoring after liver transplantation","volume":"36","author":"Langers","year":"2014","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1016\/j.bpg.2021.101756_bib94","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/00007890-199609150-00022","article-title":"Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients","volume":"62","author":"Langman","year":"1996","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.bpg.2021.101756_bib95","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1111\/j.1600-6143.2004.00617.x","article-title":"Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation","volume":"4","author":"Glander","year":"2004","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.bpg.2021.101756_bib96","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/bcp.14218","article-title":"Pharmacodynamic assessment of mycophenolic acid in resting and activated target cell population during the first year after renal transplantation","volume":"86","author":"Klaasen","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib97","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2133\/dmpk.DMPK-12-RG-048","article-title":"Monitoring of inosine monophosphate dehydrogenase activity and expression during the early period of mycophenolate mofetil therapy in de novo renal transplant patients","volume":"28","author":"Molinaro","year":"2013","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"6","key":"10.1016\/j.bpg.2021.101756_bib98","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0009-9236(98)90058-3","article-title":"The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation","volume":"64","author":"Hale","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bpg.2021.101756_bib99","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.phrs.2013.03.009","article-title":"Impact of longitudinal exposure to mycophenolic acid on acute rejection in renal-transplant recipients using a joint modeling approach","volume":"72","author":"Daher Abdi","year":"2013","journal-title":"Pharmacol Res"},{"issue":"4","key":"10.1016\/j.bpg.2021.101756_bib100","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/lt.20124","article-title":"Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range","volume":"10","author":"Tredger","year":"2004","journal-title":"Liver Transplant"},{"issue":"11","key":"10.1016\/j.bpg.2021.101756_bib101","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/j.1600-6143.2007.01983.x","article-title":"Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation","volume":"7","author":"Le Meur","year":"2007","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.bpg.2021.101756_bib102","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/FPC.0000000000000010","article-title":"PharmGKB summary: mycophenolic acid pathway","volume":"24","author":"Lamba","year":"2014","journal-title":"Pharmacogenetics Genom"},{"issue":"Suppl 1","key":"10.1016\/j.bpg.2021.101756_bib103","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/FTD.0000000000000287","article-title":"Barcelona consensus on biomarker-based immunosuppressive drugs management in solid organ transplantation","volume":"38","author":"Brunet","year":"2016","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1016\/j.bpg.2021.101756_bib104","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5500\/wjt.v10.i5.90","article-title":"Pharmacogenetics of immunosuppressant drugs: a new aspect for individualized therapy","volume":"10","author":"Salvadori","year":"2020","journal-title":"World J Transplant"},{"issue":"10","key":"10.1016\/j.bpg.2021.101756_bib105","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/tri.12382","article-title":"Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients?","volume":"27","author":"Li","year":"2014","journal-title":"Transpl Int"},{"issue":"1","key":"10.1016\/j.bpg.2021.101756_bib106","doi-asserted-by":"crossref","first-page":"11","DOI":"10.14701\/ahbps.2017.21.1.11","article-title":"Intra-individual variability of mycophenolic acid concentration according to renal function in liver transplant recipients receiving mycophenolate monotherapy","volume":"21","author":"Hwang","year":"2017","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"issue":"7","key":"10.1016\/j.bpg.2021.101756_bib107","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1517\/14740338.2015.1040388","article-title":"Everolimus and sirolimus in transplantation-related but different","volume":"14","author":"Klawitter","year":"2015","journal-title":"Expet Opin Drug Saf"},{"issue":"10","key":"10.1016\/j.bpg.2021.101756_bib108","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrneph.2016.108","article-title":"Roles of mTOR complexes in the kidney: implications for renal disease and transplantation","volume":"12","author":"Fantus","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"10.1016\/j.bpg.2021.101756_bib109","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2165\/00003088-200140080-00002","article-title":"Clinical pharmacokinetics of sirolimus","volume":"40","author":"Mahalati","year":"2001","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib110","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib111","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/TP.0000000000001438","article-title":"Use of everolimus in liver transplantation: recommendations from a working group","volume":"101","author":"De Simone","year":"2017","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.bpg.2021.101756_bib112","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s40267-017-0403-0","article-title":"A review on therapeutic drug monitoring of the mTOR class of immunosuppressants: everolimus and sirolimus","volume":"33","author":"Jacob","year":"2017","journal-title":"Drugs Ther Perspect"},{"issue":"3","key":"10.1016\/j.bpg.2021.101756_bib113","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/00007691-200206000-00004","article-title":"A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration","volume":"24","author":"McAlister","year":"2002","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/j.bpg.2021.101756_bib114","first-page":"169","article-title":"Pharmacokinetics of the immunosuppressant everolimus in maintenance renal transplant patients","volume":"10","author":"Budde","year":"2005","journal-title":"Eur J Med Res"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib115","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/FTD.0000000000000616","article-title":"Pharmacodynamic monitoring of mTOR inhibitors","volume":"41","author":"Mill\u00e1n","year":"2019","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib116","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/FTD.0000000000000260","article-title":"Therapeutic drug monitoring of everolimus: a consensus report","volume":"38","author":"Shipkova","year":"2016","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib117","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1399-0012.2005.00326.x","article-title":"Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data","volume":"19","author":"Lorber","year":"2005","journal-title":"Clin Transplant"},{"issue":"3","key":"10.1016\/j.bpg.2021.101756_bib118","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.trre.2017.02.007","article-title":"Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation","volume":"31","author":"van Gelder","year":"2017","journal-title":"Transplant Rev"},{"issue":"11","key":"10.1016\/j.bpg.2021.101756_bib119","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2012.04212.x","article-title":"Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial","volume":"12","author":"De Simone","year":"2012","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.bpg.2021.101756_bib120","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial","volume":"100","author":"Geissler","year":"2016","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.bpg.2021.101756_bib121","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1097\/TP.0000000000002980","article-title":"Randomized sirolimus-based early calcineurin inhibitor reduction in liver transplantation: impact on renal function","volume":"104","author":"Buchholz","year":"2020","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.bpg.2021.101756_bib122","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.transproceed.2008.07.029","article-title":"Impact of variability of sirolimus trough level on chronic allograft nephropathy","volume":"40","author":"Wu","year":"2008","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib123","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.transproceed.2018.08.016","article-title":"Variability of the mammalian target of rapamycin inhibitors is correlated with long-term renal graft survival","volume":"51","author":"Valero","year":"2019","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1016\/j.bpg.2021.101756_bib124","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1053\/jlts.2001.23356","article-title":"A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients","volume":"7","author":"Wiesner","year":"2001","journal-title":"Liver Transplant"},{"issue":"4","key":"10.1016\/j.bpg.2021.101756_bib125","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/FTD.0000000000000769","article-title":"Usage of tacrolimus and mycophenolic acid during conception, pregnancy, and lactation, and its implications for therapeutic drug monitoring: a systematic critical review","volume":"42","author":"Le","year":"2020","journal-title":"Ther Drug Monit"},{"issue":"8","key":"10.1016\/j.bpg.2021.101756_bib126","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1046\/j.1365-2036.2000.00812.x","article-title":"Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy","volume":"14","author":"Cuffari","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.bpg.2021.101756_bib127","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/j.1440-1746.2005.03832.x","article-title":"Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease","volume":"20","author":"Gearry","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2021.101756_bib128","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/gut.39.1.63","article-title":"Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration","volume":"39","author":"Van Os","year":"1996","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.bpg.2021.101756_bib129","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/gut.48.5.591","article-title":"Rational dosing of azathioprine and 6-mercaptopurine","volume":"48","author":"Sandborn","year":"2001","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.bpg.2021.101756_bib130","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/2040622315579063","article-title":"Optimizing the use of thiopurines in inflammatory bowel disease","volume":"6","author":"Goel","year":"2015","journal-title":"Ther Adv Chronic Dis"},{"issue":"Suppl 3","key":"10.1016\/j.bpg.2021.101756_bib131","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2021.101756_bib132","article-title":"Systematic review and meta-analysis of thiopurine metabolite levels and biochemical remission in autoimmune hepatitis","volume":"Dec 17","author":"Bolia","year":"2020","journal-title":"Ther Drug Monit"},{"issue":"6","key":"10.1016\/j.bpg.2021.101756_bib133","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/liv.14062","article-title":"Autoimmune hepatitis: current and future therapeutic options","volume":"39","author":"Doycheva","year":"2019","journal-title":"Liver Int"},{"issue":"3 Pt 1","key":"10.1016\/j.bpg.2021.101756_bib134","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1399-0012.1994.tb00244.x","article-title":"Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients","volume":"8","author":"Ohlman","year":"1994","journal-title":"Clin Transplant"},{"issue":"5","key":"10.1016\/j.bpg.2021.101756_bib135","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update","volume":"105","author":"Relling","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bpg.2021.101756_bib136","article-title":"The relationship between thiopurine S-methyltransferase genotype\/phenotype and 6-thioguanine nucleotide levels in 316 patients with inflammatory bowel disease on 6-thioguanine","volume":"Feb 1","author":"Bayoumy","year":"2021","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.bpg.2021.101756_bib137","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40291-019-00398-x","article-title":"Modeling the outcome of systematic TPMT genotyping or phenotyping before azathioprine prescription: a cost-effectiveness analysis","volume":"23","author":"Zarca","year":"2019","journal-title":"Mol Diagn Ther"},{"issue":"2","key":"10.1016\/j.bpg.2021.101756_bib138","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/0961203307085255","article-title":"Azathioprine-induced fatal myelosuppression in systemic lupus erythematosus patient carrying TPMT*3C polymorphism","volume":"17","author":"Boonsrirat","year":"2008","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.bpg.2021.101756_bib139","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/FTD.0000000000000455","article-title":"Analytical pitfalls of therapeutic drug monitoring of thiopurines in patients with inflammatory bowel disease","volume":"39","author":"Simsek","year":"2017","journal-title":"Ther Drug Monit"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691821000366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691821000366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:04:09Z","timestamp":1761498249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691821000366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":139,"alternative-id":["S1521691821000366"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2021.101756","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2021.101756","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101756"}}